Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside

Nuvama Institutional Equities has initiated coverage of Laurus Labs with a Buy rating, placing the company’s contract development and manufacturing organisation (CDMO) business at the centre of its growth outlook.

CDMO identified as key growth driver

The coverage marks a fresh research view on Laurus Labs. Nuvama’s assessment identifies CDMO as an important driver for the company, suggesting that the business is shifting toward a growth profile supported by this segment.

Nuvama sees 24% upside for Laurus Labs. The view gives investors a new broker-led reference point on the company’s prospects, although the available coverage details do not include further estimates, valuation information or operational metrics.

What the coverage means

The Buy rating represents Nuvama’s stated investment view following the start of its coverage. Its emphasis on CDMO highlights the segment’s relevance to the broader Laurus Labs story.

Further details on the assumptions behind the projected upside were not provided. For now, the key disclosed points are the Buy recommendation, the focus on CDMO and Nuvama’s expectation of 24% upside.